Kura Oncology Quote - KURA

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

15.91

Bid

15.19

Ask

17.06

Volume

0.00 Day's Range 0.00

9.06 52 Week Range 24.17

Market Cap

1.237B

Previous Close

15.91

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

603,492

Shares Outstanding

77,763,750

Dividend Yield

PE Ratio

-8.11

Earnings Per Share (EPS)

-1.96

Revenue

Net Profit

-152.63M

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progressi... Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. Show more

Sector

Pharmaceutical Preparations

Industry

Blank Checks

Website

www.kuraoncology.com

Headquarters

Wilmington, Delaware, USA

Founded

2015

Kura Oncology Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KURA. The last closing price for Kura Oncology was US$15.91. Over the last year, Kura Oncology shares have traded in a share price range of US$ 9.06 to US$ 24.17.

Kura Oncology currently has 77,763,750 shares outstanding. The market capitalization of Kura Oncology is US$1.24 billion. Kura Oncology has a price to earnings ratio (PE ratio) of -8.11.

Form 8-K - Current report

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias PR Newswire SAN DIEGO and TOKYO, Nov. 20, 2024 – Kura to receive a...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.815	-10.23977433	17.725	17.94	15.42	834014	16.04828107	CS
4	-1.94	-10.8683473389	17.85	19.7283	15.42	835540	17.30666885	CS
12	-4.4	-21.6642048252	20.31	21.569	15.42	603492	18.29757496	CS
26	-6.15	-27.878513146	22.06	23.48	15.42	648708	19.59841155	CS
52	6.49	68.8959660297	9.42	24.17	9.06	912519	18.67254163	CS
156	-1.2	-7.01344243133	17.11	24.17	7.41	845440	15.10280006	CS
260	0.79	5.22486772487	15.12	43	6.34	752112	17.95244748	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	0
AACGATA Creativity Global	US$ 1.02 (0.00%)	0
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	0
AACGATA Creativity Global	US$ 1.02 (0.00%)	0
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	0
AACGATA Creativity Global	US$ 1.02 (0.00%)	0